Motif Bio has had its Nasdaq IPO hopes crushed by an unreceptive market, leaving the late-phase antibiotic player with a hole in its spending plans.

The value of Neil Woodford’s Patient Capital Trust fell 10.8% as Circassia’s late-phase flop and the ongoing decline of Northwest Biotherapeutics hit home.

Gemphire Therapeutics managed to get its IPO out in the dog days of summer. But it languished several weeks and then had to cut its pricing expectations.

A week after microcap Tokai saw its shares plummet after the failure of its key Phase III prostate cancer candidate galeterone, the biotech has unsurprisingly…

Almost all of the biotech IPOs that have priced since the first quarter have broken issue, meaning that they are now trading below their offer price

AstraZeneca has dropped 6 drug programs from its pipeline--with almost all the early-stage candidates being axed from its MedImmune biologics arms--in what is…

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…

Biogen’s long-standing CEO Dr. George Scangos is to step down from the company in “the coming months” as the Big Biotech looks for a successor.

It’s been a torrid first half for Aegerion Pharmaceuticals that began the year with a 25% cut to its staff, but the biotech is swinging the ax again--this time…